EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeitOpen Access · CC BY 4.0

UK best practice recommendations for children and young people

Rachel E J Besser iD, Fiona Campbell, Katharine Damazer, Daniela Elleri, Kathleen M Gillespie iD, Clare Hambling iD, Rebecca Martin, Fulya Mehta, Sarinda Millar, Pooja Sachdev, Tracy Savory, Ambika Shetty und 3 weitere

Diabetic Medicine · 2025-11 · 42 (11)

DOI: 10.1111/dme.70117 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Diabetic Medicine, online erschienen am 23.09.2025. Verfasst von Rachel E J Besser und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Oxford Biomedical Research Centre, Novo Nordisk UK Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Screening for childhood type 1 diabetes (T1D) is increasing worldwide. Historically, screening has been undertaken through research programmes, but increasingly in the UK, children and young people are also being tested in clinical care. This identifies children before the onset of clinical disease through measurement of four islet autoantibodies (IAb): anti‐glutamic acid decarboxylase; anti‐insulin; anti‐IA2 tyrosine phosphatase; and anti‐zinc transporter‐8. Otherwise well individuals confirmed to have ≥2 IAb have early‐stage T1D, meaning that they are in the pre‐symptomatic phase of the disease. This is categorised into stages, where stage 1 indicates ≥2 IAb and normoglycaemia, and stage 2 the presence of ≥2 IAb and dysglycaemia. Stage 3 T1D indicates that the diagnostic threshold for T1D has been reached, which may occur with or without symptoms of diabetes. The goal of screening and monitoring programmes is to reduce the adverse clinical consequences of diabetic ketoacidosis at diagnosis and to identify children who may benefit from disease‐modifying therapies to delay or reverse progression to insulin requirement. Additional benefits include avoiding hospitalisation and preparation for the 'softer landing' into T1D. To seek these benefits, children should be monitored; yet many individuals decline follow‐up in a research context. We therefore describe a pathway suitable for children identified from both screening programmes and clinical care settings. The pathway consists of 5 themes (IAb confirmation, monitoring of individuals in early‐stage T1D, starting insulin, monitoring in single IAb positivity, and audit standards against which the pathway can be assessed during implementation).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HumansChildAdolescentUnited KingdomMass ScreeningChild, PreschoolAutoantibodiesEndocrinologySocieties, MedicalDiabetic Ketoacidosis

Stichwörter der Autor:innen

diabetic ketoacidosismonitoringpreclinicalscreeningtype 1 diabetes

Substanzen

Autoantibodies

Autor:innen und Institutionen

  • Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Children's Diabetes Centre, Leeds Children's Hospital, Leeds, UK.
  • Oxford University Hospital, Children's Psychological Medicine, Oxford, UK.
  • Royal Hospital for Children and Young People, Edinburgh, UK.
  • Diabetes and Metabolism, Bristol Medical School University of Bristol, Bristol, UK.
  • Bridge Street Surgery, Norfolk, UK.

ORCID-Profile: Rachel E J Besser, Kathleen M Gillespie, Clare Hambling, Rabbi Swaby

Förderung

  • NIHR Oxford Biomedical Research Centre
  • Novo Nordisk UK Research Foundation

Zitieren

APA

Besser, R. E. J., Campbell, F., Damazer, K., Elleri, D., Gillespie, K. M., Hambling, C., Martin, R., Mehta, F., Millar, S., Sachdev, P., Savory, T., Shetty, A., Swaby, R., Randell, T., & BSPED (2025). UK best practice recommendations for children and young people. Diabetic Medicine, 42(11). https://doi.org/10.1111/dme.70117

Vancouver

Besser REJ, Campbell F, Damazer K, Elleri D, Gillespie KM, Hambling C, et al. UK best practice recommendations for children and young people. Diabetic Medicine. 2025;42(11). doi:10.1111/dme.70117

BibTeX
@article{Besser2025,
  author = {Besser, Rachel E J and Campbell, Fiona and Damazer, Katharine and Elleri, Daniela and Gillespie, Kathleen M and Hambling, Clare and Martin, Rebecca and Mehta, Fulya and Millar, Sarinda and Sachdev, Pooja and Savory, Tracy and Shetty, Ambika and Swaby, Rabbi and Randell, Tabitha and BSPED, BSPED},
  title = {UK best practice recommendations for children and young people},
  journal = {Diabetic Medicine},
  year = {2025},
  volume = {42},
  number = {11},
  doi = {10.1111/dme.70117}
}
Kostenlos starten →